GlobeNewswire·Aug 10, 2026, 7:00 AM ET

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

Sionna Therapeutics' Phase 2a PreciSION CF trial for SION-719 failed to achieve the primary endpoint of reducing sweat chloride when added to Trikafta.
The company will not advance SION-719 as an add-on therapy to standard of care.
Potential confounders, including high variability in sweat chloride levels & differences in Trikafta exposure, are being evaluated to inform future steps for the SION-451 dual combination program.
SION-719 demonstrated good tolerability over 14 days with no serious adverse events or significant liver function trends.
The Phase 1 trial for SION-451 dual combinations with SION-2222 or SION-109 met safety, tolerability, & pharmacokinetic objectives in healthy subjects.
SION-451 combined with SION-2222 was identified as the preferred dual combination based on target coverage & data.
Most adverse events in the SION-451 + SION-2222 cohorts were mild to moderate, with two participants discontinuing due to elevated liver function tests & flu-like symptoms.
Sionna ended Q2 2026 with approximately $268.3 million in cash, equivalents, & marketable securities & plans to take actions to preserve capital.
A conference call regarding these results is scheduled for August 10, 2026, at 8:00 a.m. ET.